1. Annual report 2023
  2. Research
  3. RWEpi

RWEpi

Real World Epidemiology Research Group

RWEpi is a multidisciplinary team that includes epidemiologists, statisticians, health professionals, data scientists and pre- and post-doctoral researchers with extensive experience in the analysis and interpretation of real-world data. The main objective is to generate reliable scientific evidence by using routinely collected data from different health system settings. The group participates in national and international studies focused on understanding the natural history and determinants of multiple diseases, the safety and efficacy of new drugs and vaccines, and the implementation of methods to analyze and evaluate the quality of real-world data. It also develops research in the pediatric population and pregnant women, with the creation of a large cohort linked to the electronic medical record of the primary care of Catalonia of mothers and children; as well as on health inequalities and the role of lifestyle and environmental exposures on health.

Group projects

R+D+I PROJECTS FUNDED IN COMPETITIVE CALLS FROM ADMINISTRATIONS OR PUBLIC AND PRIVATE ENTITIES

  • Plataforma IMPACT - Programa 2 - Ciencia de Datos. (IMP/00019). Barcelona Supercomputing Center (BSC-CNS); Instituto de Salud Carlos III. 2020-2024. IP: María Aragón Pérez.

  • Impact of COVID-19 vaccination on preventing long COVID: a population-based cohort study from Catalonia. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2023. IP: Elena Roel Herranz.

  • DARWIN-EU. European Medicines Agency (EMA). 2022IP: Talita Duarte Salles.

  • Contracte Rio Hortega Elena Roel. (CM20/00174). Instituto de Salud Carlos III. 2020-2023. IP: Elena Roel Herranz.

  • Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol); ICS - Institut Català de la Salut. -2023. IP: Berta Raventós Roca.

CONTRACTS, AGREEMENTS OR NON-COMPETITIVE R+D+I PROJECTS WITH ADMINISTRATIONS OR PUBLIC OR PRIVATE ENTITIES.

  • LANTITAPS. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2023. IP:  Puente Baliarda.

CLINICAL STUDIES

  • vACCine covid-19 monitoring readinESS (ACCESS). UMC Utrecht (University Medical Center Utrecht). 2020-2023. IP: María Aragón Pérez.

  • Utilization and safety of antidementia treatments: a large longitudinal population-based study in Catalonia. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022. IP: Carlen Reyes Reyes.

  • Use of hydrochlorothiazide and risk of skin cancer. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2020-2023. IP: Talita Duarte Salles.

  • Urban and social environment and childhood obesity - a natural moving2health experiment. Fundacio "la Caixa". 2021. IP: Talita Duarte Salles.

  • UNravelling COVID-19 through rEal-woRld data (UNCOVER). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021. IP: Talita Duarte Salles.

  • ime trends and socioeconomic factors associated with cancer incidence for five solid tumour sites in Catalonia from 2009 to 2018. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022. IP: Talita Duarte Salles.

  • The descriptive epidemiology of Adverse Events of Special Interest for COVID-19 and other vaccines and after seasonal influenza and COVID-19 disease in SIDIAP. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021. IP: Talita Duarte Salles.

  • Systemic glucocorticoids in the treatment of COVID-19 and risks of adverse outcomes in COVID-19 patients in the primary and secondary care setting. IQVIA Solutions BV. 2021. IP: Talita Duarte Salles.

  • Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine. IQVIA Solutions BV. 2022. IP: Talita Duarte Salles.

  • Short term effects of temperature and air pollution on health in Barcelona and its metropolitan area considering sociodemographic and geographical inequalities. 2023. IP: Andrea Pistillo.

  • Risk of mental and behavioral disorders in relation to availability of green spaces. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021. IP: Talita Duarte Salles.

  • Residential outdoor play spaces and children's diagnosed mental and behavioural disorders: the role of individual and area-level socio economic characteristics. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2020-2023. IP: Talita Duarte Salles.

  • Research Protocol for an Observational Health Data Analysis to Assess the Long-term Outcomes of Prostate Cancer Patients Undergoing Non-Interventional Management (i.e., Watchful Waiting) and the Impact of Comorbidities and Life Expectancy - PIONEER IMI's "Big Data for Better Outcomes" program. STICHTING EUROPEAN UROLOGICAL FOUNDATION. 2021. IP: Talita Duarte Salles.

  • Real-world coverage and effectiveness of COVID-19 vaccines in vulnerable populations living in Catalonia. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2023. IP: Talita Duarte Salles.

  • Real world trends in surgical procedures- an international network study. University of Oxford. 2021. IP: Talita Duarte Salles.

  • Prevalence of rare blood cancers in Europe - DARWIN - Rare Blood Cancers (C01-001). ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC). 2022-2024. IP: Talita Duarte Salles.

  • Preliminary signal assessment in VigiBase enhanced by longitudinal observational health data: the EHDEN pharmacovigilance use case. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022. IP: Carlen Reyes Reyes.

  • Musculoskeletal adverse outcomes after treatment with aromatase inhibitors for breast cancer: a SIDIAP-OHDSI based cohort study. University of Oxford. 2020-2023. IP: Talita Duarte Salles.

  • Maternal Urban Exposures, Socioeconomic Context, and Birth Outcomes: A Population Based Longitudinal Study in Catalonia, Spain. 2023. IP: Alicia Abellan Ecija.

  • Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus. University of California, Los Angeles campus (UCLA). 2022. IP: Talita Duarte Salles.

  • Impact of EU label changes fluoroquinolone containing medicinal products for systemic and inhalation use: post-referral prescribing trends. IQVIA Solutions BV. 2021. IP: Talita Duarte Salles.

  • Examining the etiology of early-onset colorectal cancer (EOCRC) in the SIDIAP database - research protocol. International Agency for Research on Cancer (IARC). 2021. IP: Talita Duarte Salles.

  • European Non-interventional Post Authorization Safety Study for romosozumab by the EU-ADR Alliance. 2018-2026. IP: Carlen Reyes Reyes.

  • Epidemiology and burden of imminent subsequent fractures in postmenopausal women. University of Oxford. 2023. IP: Carlen Reyes Reyes.

  • Effects of temperature and air pollution on mental health in Barcelona and its metropolitan area considering sociodemographic and geographical inequalities. (74036228-32). Institut Municipal Hisenda BCN - AJUNTAMENT DE BARCELONA. 2022-2024. IP: Talita Duarte Salles.

  • Effects of Angiotensin-converting enzyme Inhibitors and Angiotensin receptor blockers: protocol for a Spanish cohort study using routinely collected electronic health records with validation against the ONTARGET trial. London School of Hygiene & Tropical Medicine. 2022. IP: Carlen Reyes Reyes.

  • Drug Utilization Study (DUS) and Post Authorization Safety Study (PASS) on the fixed combination tramadol-dexketoprofen (DKP-TRAM). SIMG - Società Italiana di Medicina Generale e delle cure primarie; SIMG SERVICE CONGRESS AND EDUCATION S.R.L. 2021. IP: Talita Duarte Salles.

  • Drug utilisation studies using data mapped to the OMOP Common Data Model: a proof of concept study assessing respiratory drug use in patients with asthma or COPD. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2021. IP: Talita Duarte Salles.

  • Drug utilisation of valproate-containing medicinal products in women of childbearing potential. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2022-2024. IP: Talita Duarte Salles.

  • DARWIN EU® - Use of take-home naloxone for opioid overdose treatment. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2024. IP: Talita Duarte Salles.

  • DARWIN EU® - Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023IP: Talita Duarte Salles.

  • DARWIN EU® - Natural history of dermatomyositis (DM) and polymyositis (PM) in adults and paediatric populations. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2024. IP: Talita Duarte Salles.

  • DARWIN EU® - Multiple myeloma: patient characterisation, treatments and survival in the period 2012-2022. 2023-2024. IP: Talita Duarte Salles.

  • DARWIN EU® - Monitoring prescription of medicines for public health emergencies at risk of shortages. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - DUS of medicines with prokinetic properties in children and adults diagnosed with gastroparesis. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2024. IP: Talita Duarte Salles.

  • DARWIN EU® - DUS of Antibiotics in the 'Watch' category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use. 2022-2024. IP: Talita Duarte Salles.

  • DARWIN EU® - DUS in patients with major depressive disorder. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023. IP: Talita Duarte Salles.

  • DARWIN EU® - Drug utilization study of prescription opioids. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2024. IP: Talita Duarte Salles.

  • DARWIN EU - EHDS Use Case: Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV-2 in the context of the OMICRON variant. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023. IP: Talita Duarte Salles.

  • DARWIN EU - Background rates of serious adverse events to contextualise safety signals in a clinical trial in adolescent and adult patients with severe asthma. 2023-2024. IP: Talita Duarte Salles.

  • Cohorte DESVELA. Análisis del papel de las aptitudes personales como DEterminantes de la incidencia de morbilidad, eStilos de vida, calidad de Vida, uso de sErvicios y mortaLidAd. (PI19/01285). Instituto de Salud Carlos III. 2019-2024. IP: Diana Puente Baliarda, Bonaventura Bolíbar Ribas.

  • Characterisation and risks of long-term COVID-19 outcomes using large real world data. Instituto de Salud Carlos III. 2022. IP: Talita Duarte Salles.

  • Associations between playspaces and childhood overweight and obesity in Barcelona. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021. IP: Talita Duarte Salles.

  • Anàlisi de perfils d'hiperfreqüentació de serveis sanitaris en Atenció Primària. 2023-2026. IP: Sergio Fernández Bertolín.

  • Air pollution in relation to COVID-19 morbidity and mortality: a large population-based cohort study in Catalonia, Spain (COVAIR-CAT). Fundación Privada Instituto de Salud Global Barcelona (ISGlobal). 2022. IP: Talita Duarte Salles.

  • Drug Utilization Study Evaluating Additional Risk Minimization Measures for Upadacitinib in the Treatment of Atopic Dermatitis in Europe. Abbvie INC. IP: Talita Duarte Salles.

Group publications

JOURNAL PUBLICATIONS

  • Pou MA, Martinez Laguna D, Estebanez JL, Aivar M, Gayarre R, Conesa A et al. Validation of gout diagnosis in electronic primary care medical records: A population-based study. Jt. Bone Spine. 2023;90(6):105628-105628. PMID:37634875.

  • Raventos B, Fernandez Bertolin S, Aragon M, Voss EA, Blacketer C, Mendez Boo L et al. Transforming the Information System for Research in Primary Care (SIDIAP) in Catalonia to the OMOP Common Data Model and Its Use for COVID-19 Research. Clin. Epidemiol. 2023;15969-986. PMID:37724311.

  • Bennett M, Pistillo A, Recalde M, Reyes C, Freisling H, Duarte Salles T. Time trends in the incidence of cardiovascular disease, hypertension and diabetes by sex and socioeconomic status in Catalonia, Spain: a population-based cohort study. BMJ Open. 2023;13(5):  PMID:37225269.

  • Gauffin O, Brand JS, Vidlin SH, Sartori D, Asikainen S, Català M et al. Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network Study. Drug Saf. 2023;46(12):1335-1352. PMID:37804398.

  • Arshad F, Schuemie MJ, Bu F, Minty EP, Alshammari TM, Lai LYH et al. Serially Combining Epidemiological Designs Does Not Improve Overall Signal Detection in Vaccine Safety Surveillance. Drug Saf. 2023;46(8):797-807. PMID:37328600.

  • You SC, Seo SI, Falconer T, Yanover C, Duarte Salles T, Seager S et al. Ranitidine Use and Incident Cancer in a Multinational Cohort. JAMA Netw Open. 2023;6(9):2333495-PMID:37725377.

  • Navarro J, Curran A, Raventos B, Garcia J, Suanzes P, Descalzo V et al. Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain. Eur. J. Intern. Med. 2023;11054-61. PMID:36764905.

  • Khera R, Dhingra LS, Aminorroaya A, Li K, Zhou JJ, Arshad F et al. Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM. BMJ Med. 2023;2(1): PMID:37829182.

  • Ranzani O, Alari A, Olmos S, Milà C, Rico A, Ballester J et al. Long-term exposure to air pollution and severe COVID-19 in Catalonia: a population-based cohort study. Nat Commun. 2023;14(1):2916-2916. PMID:37225741.

  • Recalde M, Pistillo A, Davila Batista V, Leitzmann M, Romieu I, Viallon V et al. Longitudinal body mass index and cancer risk: a cohort study of 2.6 million Catalan adults. Nat Commun. 2023;14(1):3816-3816. PMID:37391446.

  • Raventós B, Català M, Du MK, Guo YC, Black A, Inberg G et al. IncidencePrevalence: An R package to calculate population-level incidence rates and prevalence using the OMOP common data model. Pharmacoepidemiol. Drug Saf. 2023;33(1): PMID:37876360.

  • Ochoa Gondar O, Torras Vives V, De Diego Cabanes C, Satué Gracia EM, Vila Rovira A, Forcadell Perisa MJ et al. Incidence and risk factors of pneumococcal pneumonia in adults: a population-based study. BMC Pulm. Med. 2023;23(1):200-200. PMID:37291502.

  • LYNF, Flach C, Lysen TS, Markov E, van Ballegooijen H, Rijnbeek P et al. Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-Referral Prescribing Trends. Drug Saf. 2023;46(4):405-416. PMID:36976448.

  • Vásquez Vera C, Fernández A, Sánchez Ledesma E, Bennett M, Borrell C. Gender-based differences in the meanings and uses of housing for health and everyday life: An intersectional approach. Women's Stud. Int. Forum. 2023;99

  • Makadia R, Shoaibi A, Rao GA, Ostropolets A, Rijnbeek PR, Voss EA et al. Evaluating the impact of alternative phenotype definitions on incidence rates across a global data network. JAMIA Open. 2023;6(4): PMID:38028730.

  • Tan EH, Robinson DE, Joedicke AM, Mosseveld M, Bodkergaard K, Reyes C et al. Drug utilization analysis of osteoporosis medications in seven European electronic health databases. Osteoporosis Int. 2023;34(10):1771-1781. PMID:37436441.

  • Arinze JT, de Ridder M, Vojinovic D, van Ballegooijen H, Markov E, Duarte Salles T et al. Drug Utilisation Patterns of Alternatives to Ranitidine-Containing Medicines in Patients Treated with Ranitidine: A Network Analysis of Data from Six European National Databases. Drug Saf. 2023;46(12):1353-1362. PMID:37907775.

  • Voss EA, Shoaibi A, Yin Hui Lai L, Blacketer C, Alshammari T, Makadia R et al. Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. EClinicalMedicine. 2023;58101932-101932. PMID:37034358.

  • Moreno Martos D, Verhamme K, Ostropolets A, Kostka K, Duarte Sales T, Prieto Alhambra D et al. Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe. Wellcome Open Res. 2023;7

  • Markus AF, Strauss VY, Burn E, Li XT, Delmestri A, Reich C et al. Characterising the treatment of thromboembolic events after COVID-19 vaccination in 4 European countries and the US: An international network cohort study. Front. Pharmacol. 2023;141118203-1118203. PMID:37033631.

  • Warkentin S, de Bont J, Abellan A, Pistillo A, Saucy A, Cirach M et al. Changes in air pollution exposure after residential relocation and body mass index in children and adolescents: A natural experiment study?. Environ. Pollut. 2023;334122217-122217. PMID:37467916.

  • Recalde M, Pistillo A, Viallon V, Fontvieille E, Duarte Salles T, Freisling H. Body mass index and incident cardiometabolic conditions in relation to obesity-related cancer risk: A population-based cohort study in Catalonia, Spain. Cancer Med. 2023;12(19):20188-20200. PMID:37766588.

  • Kostka K, Roel E, Trinh NTH, Mercadé Besora N, Delmestri A, Mateu L et al. "The burden of post-acute COVID-19 symptoms in a multinational network cohort analysis". Nat Commun. 2023;14(1):7449-7449. PMID:37978296.

PROCEEDING PAPERS

  • Arinze JT, de Ridder M, Duarte Salles T, Sabaté MC, Delmestri A, Omulo H et al. Use of antibiotics in the 'watch' category of the WHO AWaRe classification in Europe: A DARWIN-EU® multinational network cohort study (EUPAS103381). Pharmacoepidemiol. Drug Saf. 2023;32148-149.

  • Reyes C, Newby D, Burn E, Raventós B, Duarte Salles T. Trends in the prescription of anti-dementia treatments in Spain and the UK: A large network population-based cohort study. Pharmacoepidemiol. Drug Saf. 2023;32367-367.

  • Lóez Sánchez I, Raventós B, Roel E, Duarte Salles T. Socioeconomic inequalities in vaccine uptake among children and adolescents in Catalonia, Spain. Gac. Sanit. 2023;37158-158.

  • Pistillo A, Warkentin S, Abellan A, Cirach M, Perramon Malavez A, Nieuwenhuijsen M et al. Patterns of environmental exposures related to residential relocation in catalonia: a quasi-experimental study. Gac. Sanit. 2023;37127-127.

  • López Jiménez T, Plana Ripoll O, Duarte Salles T, Recalde M, Bennett M, Puente D. Metabolic syndrome components and cancer risk in catalonia: a large population-based cohort study. Gac. Sanit. 2023;37231-231.

  • Vásquez Vera C, Fernández A, Sánchez Ledesma E, Bennett M, Borrell C. Meanings and uses of housing for daily life and health: gender inequalities from an intersectional perspective. Gac. Sanit. 2023;37125-125.

  • Kostka K, Roel E, Trinh N, Delmestri A, Mateau L, Paredes R et al. Long COVID symptoms following primo- versus reinfection: A multinational cohort analysis of primary care records from Catalonia and the UK. Pharmacoepidemiol. Drug Saf. 2023;32205-206.

  • Raventós B, Reyes C, Aragonès E, Newby D, Mayer MA, Prieto Alhambra D et al. Impact of the covid-19 pandemic on prescription trends of psychotropic medications. Gac. Sanit. 2023;37120-121.

  • Warkentin S, Pistillo A, Abellan A, Raventós B, de Bont J, Vrijheid M et al. Impact of the covid-19 pandemic on childhood and adolescent overweight/obesity in Catalonia, Spain. Gac. Sanit. 2023;37251-251.

  • Raventos B, Fernández Bertolín S, Weaver J, Blacketer C, Aragón M, Recalde M et al. Establishing and characterizing large COVID-19 cohorts after mapping the information system for research in primary care (SIDIAP) in Catalonia to the OMOP common data model. Pharmacoepidemiol. Drug Saf. 2023;32211-211.

  • Warkentin S, de Bont J, Abellan A, Pistillo A, Saucy A, Cirach M et al. Effect of residential relocation on air pollution exposure and child body mass index. Gac. Sanit. 2023;3788-88.

  • Besora NM, Prieto Alhambra D, Roel E, Delmestri A, Prats C, Jödicke AM et al. Effect of COVID-19 vaccines on post-COVID cardiac and thromboembolic complications. Pharmacoepidemiol. Drug Saf. 2023;32625-626.

  • Besora NM, Jödicke AM, Roel E, Delmestri A, Prats C, Prieto Alhambra D et al. Effect of COVID-19 vaccination on thromboembolic and cardiovascular complications following SARS-CoV-2 infection. Pharmacoepidemiol. Drug Saf. 2023;3243-43.

  • Li XT, Sabaté MC, Raventós B, Du M, Guo YC, Guëll KL et al. Bespoke code versus off-the-shelf R package in calculating incidence rates using real-world data. Pharmacoepidemiol. Drug Saf. 2023;32417-418.

  • Li XT, Raventós B, Guo YC, Du MK, Burn E, Prieto Alhambra D et al. Agreement of COVID-19 incidence between the authoritative data and real-world evidence in England. Pharmacoepidemiol. Drug Saf. 2023;32442-442.

Anar a l'inici